X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The Company intends to use the net proceeds from the Offering, including the Final Tranche, to fund its research, development, and commercialization activities for Rotigotine and for general working capital purposes.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 27, 2023
Details:
The Company intends to use the net proceeds to fund its research, development, and commercialization activities of its drug canditates, including Rotigotine, a non-ergoline dopamine agonist approved for the treatment of Parkinson's disease and restless legs syndrome.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 28, 2023
Details:
The Company intends to use the net proceeds from the offering, including the first tranche, to fund its research, development, and commercialization activities of rotigotine and for general working capital purposes.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 28, 2023
Details:
The Company intends to use the net proceeds for research, development, and commercialization programs including,
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 04, 2023
Details:
Rotigotine transdermal patch is a non-ergoline dopamine agonist for the treatment of Parkinson's disease and restless legs syndrome (RLS) in Europe and the United States.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
The Company intends to use the net proceeds from the Offering for research, development, and commercialization programs.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2023
Details:
Rotigotine is a non-ergoline dopamine agonist approved for the treatment of Parkinson's disease and restless legs syndrome (RLS) in Europe and the United States.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2023
Details:
Rotigotine transdermal patch is used to treat Parkinson disease. It is a dopamine agonist that works on the nervous system to help treat the symptoms of Parkinson disease. Rotigotine is also used to treat a condition called Restless Legs Syndrome (RLS).
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Rotigotine is non-ergoline dopamine agonist approved for treatment of Parkinson’s disease and restless legs syndrome.Active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: ROV045
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
The company will use net proceeds of the financing to fund its research, development and commercialization activities for its lead Rotigotine and other pipeline candidates and for general working capital.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.6 million Upfront Cash: Undisclosed
Deal Type: Financing September 02, 2022
Details:
The Company will use net proceeds of the placement to fund its research, development and commercialization activities especially for it's lead rotigotine and for general working capital.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: ROV045
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 31, 2022
Details:
Rotigotine improved executive function, which helps patients with key cognitive tasks, such as reasoning, judgment, working memory, and orientation. It also improved their ability to complete routine daily activities.
Lead Product(s): Rotigotine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
